In this article, we discuss the top 5 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. If you want our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, go directly to the Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital.
5. Sutro Biopharma, Inc. (NASDAQ:STRO)
Samsara BioCapital’s Stake Value: $31.65 million
Percentage of Samsara BioCapital’s 13F Portfolio: 4.96%
Number of Hedge Fund Holders: 23
Sutro Biopharma, Inc. (NASDAQ:STRO), previously known as Fundamental Applied Biology, Inc., is a biopharmaceutical company driven on clinical-stage discovering, developing, and producing drugs. The company’s work focuses on cancer and autoimmune therapeutics. The firm is in a license agreement with Merck & Co Inc (NYSE:MRK) and Celgene Corporation.
On November 17, Berenberg analyst Zhiqiang Shu assumed the coverage of Sutro Biopharma, Inc. (NASDAQ:STRO) stock with a price target of $30.
According to the database of Insider Monkey that tracks 867 hedge funds, 23 funds held stakes in Sutro Biopharma, Inc. (NASDAQ:STRO) worth $213.8 million in the third quarter, down from 26 funds holding stakes worth $223.15 million in the previous quarter.
4. Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX)
Samsara BioCapital’s Stake Value: $36.3 million
Percentage of Samsara BioCapital’s 13F Portfolio: 5.69%
Number of Hedge Fund Holders: 16
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) is a Massachusetts-based biopharmaceutical company that develops clinical-stage drugs for the treatment of rare blood diseases and cancer.
According to the database of Insider Monkey, RA Capital Management has the most significant stake in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) with 9.01 million shares worth $208.98 million, making up 2.89% of the portfolio. The second position is occupied by Boston-based Cormorant Asset Management with shares worth $109.46 in the third quarter of 2021.
According to the third quarter filings, Samsara BioCapital owned 1.56 million shares in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) worth $36.3 million, representing 5.69% of the portfolio.
3. Instil Bio, Inc. (NASDAQ:TIL)
Samsara BioCapital’s Stake Value: $38.34 million
Percentage of Samsara BioCapital’s 13F Portfolio: 6.01%
Number of Hedge Fund Holders: 11
Instil Bio, Inc. (NASDAQ:TIL) is a publicly held biotechnology company based in Texas. It develops treatments using cell therapy against cancer, specifically utilizing autologous tumor infiltrating-lymphocytes (TIL).
On December 8, Baird analyst Jack Allen assumed coverage of Instil Bio, Inc. (NASDAQ:TIL) stock with an Outperform rating and the price target of $34.
2. Nkarta, Inc. (NASDAQ:NKTX)
Samsara BioCapital’s Stake Value: $56.58 million
Percentage of Samsara BioCapital’s 13F Portfolio: 8.87%
Number of Hedge Fund Holders: 10
Nkarta, Inc. (NASDAQ:NKTX) is a biotech company involved in developing and manufacturing allogeneic engineered natural killer (NK) cell therapies to fight against cancer.
In October 2021, the signing of a strategic platform license was announced between Nkarta, Inc. (NASDAQ:NKTX) and MaxCyte, Inc. (NASDAQ:MXCT). As per the agreement, Nkarta, Inc. (NASDAQ:NKTX) would have non-exclusive clinical and commercial rights to utilize MaxCyte’s Flow Electroporation technology and ExPERT platform.
As per the database of Insider Monkey, the leading shareholder in Nkarta, Inc. (NASDAQ:NKTX) is Peter Kolchinsky’s RA Capital Management with 5.6 million worth $155.87 million, making up 2.15% of the fund’s portfolio.
1. Graphite Bio, Inc. (NASDAQ:GRPH)
Samsara BioCapital’s Stake Value: $121.8 million
Percentage of Samsara BioCapital’s 13F Portfolio: 19.11%
Number of Hedge Fund Holders: 16
Graphite Bio, Inc. (NASDAQ:GRPH) operates as a clinical-stage gene-editing company. The company was previously known as Integral Medicines, Inc. till August 2020. With precision gene correction, the firm aims to cure and treat a number of life-threatening diseases like sickle cell disease, X-linked severe combined immunodeficiency syndrome, and Gaucher disease.
Out of the 867 hedge funds tracked by Insider Monkey, 16 funds held stakes in Graphite Bio, Inc. (NASDAQ:GRPH) worth $321.66 million in the third quarter of the year, down from 22 funds holding stakes worth $623.03 million in the preceding quarter.
According to the filings of the third quarter of 2021, Samsara BioCapital’s largest holding is Graphite Bio, Inc. (NASDAQ:GRPH) with 7.43 million shares worth $121.8 million, representing 19.11% of the hedge fund’s portfolio.
You can also take a peek at Billionaire Israel Englander is Buying These 10 Stocks and 10 Value Stocks to Buy According to Billionaire Paul Tudor Jones.
